Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype.

Hepatitis C virus (HCV) is a highly variable infectious agent, classified into 8 genotypes and 86 subtypes. Our laboratory has implemented an in-house developed high-resolution HCV subtyping method based on next-generation sequencing (NGS) for error-free classification of the virus using phylogenetic analysis and analysis of genetic distances in sequences from patient samples compared to reference sequences. During routine diagnostic, a sample from an Equatorial Guinea patient could not be classified into any of the existing subtypes. The whole genome was analyzed to confirm that the new isolate could be classified as a new HCV subtype. In addition, naturally occurring resistance-associated substitutions (RAS) were analyzed by NGS. Whole-genome analysis based on p-distances suggests that the sample belongs to a new HCV genotype 1 subtype. Several RAS in the NS3 (S122T, D168E and I170V) and NS5A protein (Q(1b)24K, R(1b)30Q and Y93L+Y93F) were found, which could limit the use of some inhibitors for treating this subtype. RAS studies of new subtypes are of great interest for tailoring treatment, as no data on treatment efficacy are reported. In our case, the patient has not yet been treated, and the RAS report will be used to design the most effective treatment.

Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.

AIM: We describe the effectiveness and safety of the interferon-free regimen ombitasvir/paritaprevir/ritonavir plus dasabuvir with or without ribavirin (OBV/PTV/r ± DSV ± RBV) in a nationwide representative sample of the hepatitis C virus (HCV) monoinfected and human immunodeficiency virus-1/hepatitis C virus (HIV/HCV) coinfected population in Spain. MATERIAL AND METHODS: Data were collected from patients infected with HCV genotypes 1 or 4, with or without HIV-1 coinfection, treated with OBV/PTV/r ± DSV ± RBV at 61 Spanish sites within the initial implementation year of the first government-driven "National HCV plan." Effectiveness was assessed by sustained virologic response at post-treatment week 12 (SVR12) and compared between monoinfected and coinfected patients using a non-inferiority margin of 5% and a 90% confidence interval (CI). Sociodemographic and clinical characteristics or patients and adverse events (AEs) were also recorded. RESULTS: Overall, 2,408 patients were included in the intention-to-treat analysis: 386 (16%) were patients with HIV/HCV. Patient selection reflected the real distribution of patients treated in each participating region in Spain. From the total population, 96.6% (95% CI, 95.8-97.3%) achieved SVR12. Noninferiority of SVR12 in coinfected patients was met, with a difference between monoinfected and coinfected patients of -2.2% (90% CI, -4.5% - 0.2%). Only genotype 4 was associated with non-response to OBV/PTV/r ± DSV ± RBV treatment (p<0.001) in the multivariate analysis. Overall, 286 patients (11.9%) presented AEs potentially related to OBV/PTV/r ± DSV, whereas 347 (29.0%) presented AEs potentially related to ribavirin and 61 (5.1%) interrupted ribavirin. CONCLUSIONS: Our results confirm that OBV/PTV/r ± DSV ± RBV is effective and generally well tolerated in a representative sample of the HCV monoinfected and HCV/HIV coinfected population in Spain within the experience of a national strategic plan to tackle HCV.

[Clivus metastasis from hepatocarcinoma associated with transarterial hepatic chemoembolization]. / Metástasis en clivus de hepatocarcinoma asociado a quimiembolización transarterial hepática.

Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world, and its incidence has increasing in the latest years. Recent advances in both, diagnosis and treatment, have improved the prognosis. Transarterial chemoembolization (TACE) is a therapeutic option, valid for patients who are not candidates for curative treatments, which has demonstrate to improve survival. Complications of TACE are very frequent and often severe. Postembolization syndrome is extremely frequent. Liver abscess, acute pancreatitis, acute cholecistitis, biloma, intestinal ischemia, gastroduodenal ulcerations and liver failure, are less frequent complications. Recently, it has been described an increasing risk of distant metastasis after transarterial chemoembolization. Most frequent metastasis are in the lung, abdominal lymph nodes, bone, and suprarenal glands. Metastases in nervous system, especially in clivus, are rarely. We report the case of a patient with hepatocellular carcinoma treated with transarterial chemoembolization who was diagnosed with metastasis in clivus.

Metástasis en clivus de hepatocarcinoma asociado a quimiembolización transarterial hepática / Clivus metastasis from hepatocarcinoma associated with transarterial hepatic chemoembolization

El carcinoma hepatocelular (CHC) es la quinta causa de cáncer en el mundo, con una incidencia creciente. Los avances en el diagnóstico y el tratamiento han mejorado su pronóstico. La quimioembolización transarterial (QET) es una opción terapéutica válida para pacientes no candidatos a tratamientos curativos, que ha demostrado mejorar la supervivencia. Las complicaciones asociadas a la QET son frecuentes y, en ocasiones, graves. El síndrome postembolización es la complicación más frecuente. El absceso hepático, la pancreatitis, la colecistitis, la formación de biloma, la isquemia intestinal, la úlcera gastroduodenal y el fallo hepático son complicaciones menos frecuentes. Recientemente, se ha descrito un aumento en la incidencia de metástasis a distancia en pacientes que previamente recibieron QET. Las metástasis extrahepáticas más frecuentes del CHC se dan en pulmón, ganglios abdominales, sistema óseo y glándulas suprarrenales. Las metástasis cerebrales y, concretamente en clivus, son excepcionales. El caso que presentamos es el de un paciente afectado de CHC al que, tras recibir varias sesiones de QET, se le diagnostica metástasis en clivus

Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world, and its incidence has increasing in the latest years. Recent advances in both, diagnosis and treatment, have improved the prognosis. Transarterial chemoembolization (TACE) is a therapeutic option, valid for patients who are not candidates for curative treatments, which has demonstrate to improve survival. Complications of TACE are very frequent and often severe. Postembolization syndrome is extremely frequent. Liver abscess, acute pancreatitis, acute cholecistitis, biloma, intestinal ischemia, gastroduodenal ulcerations and liver failure, are less frequent complications. Recently, it has been described an increasing risk of distant metastasis after transarterial chemoembolization. Most frequent metastasis are in the lung, abdominal lymph nodes, bone, and suprarenal glands. Metastases in nervous system, especially in clivus, are rarely. We report the case of a patient with hepatocellular carcinoma treated with transarterial chemoembolization who was diagnosed with metastasis in clivus

Metástasis en clivus de hepatocarcinoma asociado a quimiembolización transarterial hepática / Clivus metastasis from hepatocarcinoma associated with transarterial hepatic chemoembolization

El carcinoma hepatocelular (CHC) es la quinta causa de cáncer en el mundo, con una incidencia creciente. Los avances en el diagnóstico y el tratamiento han mejorado su pronóstico. La quimioembolización transarterial (QET) es una opción terapéutica válida para pacientes no candidatos a tratamientos curativos, que ha demostrado mejorar la supervivencia. Las complicaciones asociadas a la QET son frecuentes y, en ocasiones, graves. El síndrome postembolización es la complicación más frecuente. El absceso hepático, la pancreatitis, la colecistitis, la formación de biloma, la isquemia intestinal, la úlcera gastroduodenal y el fallo hepático son complicaciones menos frecuentes. Recientemente, se ha descrito un aumento en la incidencia de metástasis a distancia en pacientes que previamente recibieron QET. Las metástasis extrahepáticas más frecuentes del CHC se dan en pulmón, ganglios abdominales, sistema óseo y glándulas suprarrenales. Las metástasis cerebrales y, concretamente en clivus, son excepcionales. El caso que presentamos es el de un paciente afectado de CHC al que, tras recibir varias sesiones de QET, se le diagnostica metástasis en clivus

Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world, and its incidence has increasing in the latest years. Recent advances in both, diagnosis and treatment, have improved the prognosis. Transarterial chemoembolization (TACE) is a therapeutic option, valid for patients who are not candidates for curative treatments, which has demonstrate to improve survival. Complications of TACE are very frequent and often severe. Postembolization syndrome is extremely frequent. Liver abscess, acute pancreatitis, acute cholecistitis, biloma, intestinal ischemia, gastroduodenal ulcerations and liver failure, are less frequent complications. Recently, it has been described an increasing risk of distant metastasis after transarterial chemoembolization. Most frequent metastasis are in the lung, abdominal lymph nodes, bone, and suprarenal glands. Metastases in nervous system, especially in clivus, are rarely. We report the case of a patient with hepatocellular carcinoma treated with transarterial chemoembolization who was diagnosed with metastasis in clivus